Across 8 pooled trials in 342 adults, NMN did not improve blood sugar, insulin or cholesterol compared with a dummy pill (Meta-analysis). It does raise blood levels of NAD+, a molecule your cells need for energy. So NMN works as a NAD+ booster, but whether that makes you healthier is still unproven.
The excitement started in mice. The mice that improved got 300 mg of NMN per kilo of body weight a day by mouth, or 500 mg by injection. For a 60 kg adult, human trials have used about 4 to 33 mg per kilo (Meta-analysis). The review’s authors say this gap may help explain why the human results look weaker.
What NMN Is (and Is Not)
NMN is short for nicotinamide mononucleotide, a building block made from a form of vitamin B3. Your cells turn it into NAD+, a helper molecule they need to get energy from food and to repair damage. The capsule holds that raw material, not NAD+ itself.
The theory behind the market is simple. NAD+ levels are thought to fall as we age. If a capsule could top them back up, cells might act younger.
NMN has a close cousin, NR (nicotinamide riboside). Our NMN vs NR breakdown covers the first trial to test the two head to head. This article sticks to NMN.
Does NMN Work for Blood Sugar?
NMN clearly moves a blood marker, a number on a lab report. The harder question is whether it changes things you would notice, like blood sugar control or strength.
In one trial in India, 80 healthy adults aged 40 to 65 took a dummy pill or 300, 600 or 900 mg of NMN a day for 60 days (Trial). A coin flip decided who got what. On NMN, blood NAD+ rose to roughly three to six times its starting level. It stopped climbing at 600 mg, and 900 mg added nothing clear on top. The blood test counted NAD+ together with a close chemical partner.
Five of the 8 trials in the 2024 review covered below also reported higher blood NAD+, though the review did not combine those results (Meta-analysis).
The best human result for NMN so far came from a 10-week trial in 25 overweight or obese women past menopause. All had prediabetes, meaning blood sugar above normal but below the diabetes level. Thirteen took 250 mg of NMN a day, and 12 took a dummy pill (Trial). In the NMN group, muscle responded to insulin about 25% better than before. The placebo group did not change. The authors compared the gain to what losing about 10% of body weight might bring.
The gain was narrow. Insulin worked no better in the liver or in fat tissue (Study). The women did not lose weight. Their body fat, liver fat, blood pressure, fasting blood sugar, insulin and blood fats all stayed the same. NAD+ rose in their blood cells but not in their muscle, so it is unclear how the gain happened.
The pooled trials found much less. A 2024 review combined 8 double-blind trials in 342 middle-aged and older adults, most of them without diabetes. In a double-blind trial, neither the volunteers nor the researchers know who got the real pill. Doses ran from 250 to 2,000 mg a day, for two to 12 weeks (Meta-analysis).
NMN did not improve fasting blood sugar, fasting insulin or HbA1c, a three-month average of blood sugar. The HbA1c result rests on just 2 small trials that disagreed with each other. Blood fats did not move either, including total cholesterol, “bad” LDL, “good” HDL and triglycerides (Meta-analysis).
The closest thing to a signal was a small drop in insulin resistance. That is a measure of how poorly the body responds to insulin. The drop was small enough that chance could explain it. It also vanished when the authors removed one trial. In that trial, the gap came from the placebo group getting worse, not from the NMN group getting better (Meta-analysis).
A larger 2026 review of 15 trials agreed, though some of its trials used closely related forms of NMN. It found no clear change in body weight, blood sugar, HbA1c or blood fats (Meta-analysis).
This verdict has one limit. Of the 8 trials in the 2024 review, only the prediabetes study enrolled people whose blood sugar was already off. The authors say their result cannot be applied to people with diabetes or high cholesterol (Meta-analysis). For those people, NMN has not been ruled out. It simply has not been tested well.
Muscle, Walking and Endurance
Most fitness claims rest on one small trial with a catch.
In Japan, 42 healthy men aged 65 and over took 250 mg of NMN or a dummy pill daily for 12 weeks (Trial). Blood NAD+ rose. Walking speed and left-hand grip improved slightly, but the authors said larger studies must confirm it. Right-hand grip and muscle mass showed no clear change overall. Neither did a chair-stand test, which times how fast you can get up from a chair.
Then came a mix-up. At six weeks, 11 men in each group were given the other group’s capsules by mistake (Trial). The researchers dropped their 12-week results, which left just 10 men per group. The NMN men who remained were also faster walkers at the start. Mitsubishi Corporation Life Sciences paid for the study and supplied the NMN. Three of its employees were among the authors.
The Indian trial also measured a six-minute treadmill walk (Trial). By day 60, people on 600 or 900 mg walked roughly 150 meters farther, while the placebo group stayed flat. But walking was a side question, not the trial’s main one. The starting distances were also near the bottom of the normal range.
Runners got a trial too. Forty-eight amateur runners took a dummy pill or 300, 600 or 1,200 mg of NMN a day for six weeks (Trial). All of them trained five to six times a week. The two higher doses helped runners use more oxygen at moderate effort, around the point where breathing starts to speed up. But their VO2max, the standard measure of peak aerobic fitness, rose no more on NMN than on the dummy pill (Trial).
Pooling the trials gives a clearer answer. A 2025 review combined six NMN trials in adults with an average age of 60 or older (Meta-analysis). NMN did not beat the dummy pill on muscle mass, grip strength, walking speed or the chair-stand test. The authors concluded that the evidence does not support NMN for keeping muscle and strength at this age.
One earlier review leans the other way. It pooled 9 trials with 412 middle-aged and older people and found a small gain in walking speed, only just clear of chance (Meta-analysis). Its summary then called that an effect on muscle mass, which it is not. At best, the muscle evidence is mixed.
One of the longest trials also came up empty. After 24 weeks, NMN did not improve grip strength or walking speed in 14 older men with diabetes (Trial).
Sleep, Energy and Biological Age
Claims about better sleep and more energy rest mostly on one Japanese trial. It enrolled 108 adults aged 65 and over, who took 250 mg of NMN or a dummy pill daily for 12 weeks (Trial). Some took it in the morning and some in the evening, which made four groups of 27.
By the end, everyone slept better, including both placebo groups. NMN did not improve sleep quality more than the dummy pill did. Evening NMN eased daytime drowsiness, but so did the evening dummy pill. Tiredness scores dropped a little overall, and NMN added nothing beyond what the dummy pill did (Trial). Every group also got faster on the chair-stand test, though evening NMN improved the most.
The authors reported a placebo effect themselves. They think some volunteers may have believed their dummy pill was NMN (Trial). Sleep was judged only by the volunteers’ own reports. Nobody measured NAD+ or any other blood marker. Mitsubishi Corporation Life Sciences, which supplied the NMN, also paid for this trial.
Then there is biological age, an estimate of how old your body seems rather than your age in years. The Indian trial estimated it with Aging.AI, a calculator from Insilico Medicine that uses 19 routine blood test values (Trial). Over 60 days, the NMN groups’ scores stayed flat. The placebo group’s score rose by about 5.6 years.
So NMN made no one younger on this measure. Instead, the placebo group, which started out the youngest, got older on paper. The authors say other age clocks and longer trials are needed.
Who paid matters here too. Two NMN makers, Aba Chemicals and Abinopharm, fully funded the trial (Trial). Three authors, including the first author, worked for those companies.
Epigenetic clocks estimate age from chemical tags on DNA. In our search, we found no published NMN trial that reports one. A trial built to test this plans to give 240 adults either 350 mg a day or a dummy pill for a year (Registry). It is still recruiting and has posted no results.
Safety and the Doses Tested
The safety news is reassuring, but it only covers the short term.
The most direct safety test followed 31 healthy adults aged 20 to 65. They took 1,250 mg of NMN or a dummy pill daily for 4 weeks (Trial). Blood counts, other blood tests and measures of body fat and muscle showed no worrying changes. A few urine readings fell outside normal ranges, in both groups.
People reported 5 side complaints, 4 on NMN and 1 on placebo. They included a cold, raised blood pressure, acne and loose stools. All were mild or moderate, and the researchers judged that none was caused by NMN. The NMN maker, Mitsubishi Corporation Life Sciences, paid for the trial. Five of the six authors work for it.
One trial gave 2,000 mg a day to 21 overweight or obese adults for 28 days (Trial). That is the top of the dose range in both reviews. There were no serious side effects, and side effects were about as common as on placebo. Liver tests did not change, and nobody reported flushing. Metro International Biotech, which makes this form of NMN, sponsored the trial.
A 2026 review pooled the safety data from 10 trials and 383 people (Meta-analysis). Compared with placebo, NMN did not raise side effects, serious side effects or the number of people who quit over them. Nor did it raise liver enzymes, a blood sign of liver strain. The authors still warn that small, short trials cannot rule out rare or delayed harms.
The 2024 review saw a possible trend toward more side complaints at 1,000 mg a day or more. NMN may not have caused them (Meta-analysis). Some NMN taken by mouth turns into nicotinamide, a form of vitamin B3 with an upper limit of 900 mg a day. The authors say that limit is worth keeping in mind at higher NMN doses.
Trials in that review most often used 250 mg a day (Meta-analysis). In the Indian trial, blood NAD+ stopped rising beyond 600 mg (Trial). No dose has a proven health benefit, so there is no “right” dose. There are only doses that look safe for a few weeks or months.
Legal status is a separate question. In September 2025, the US FDA said NMN can legally count as a dietary supplement, reversing its 2022 view (Letter). NMN still counts as a new dietary ingredient. Makers owe the FDA a required notice before sale. The FDA said they cannot skip it by declaring NMN safe themselves. Even when the FDA accepts such a notice, that is not a finding that the product is safe.
In the EU, NMN is a novel food, a legal category for new foods that need approval before sale. In May 2026, the EU food-safety agency published an opinion on one maker’s NMN. It judged that NMN safe for adults at up to 300 mg a day (Opinion). Its verdict did not cover pregnant or breastfeeding women. The opinion is not a sales approval. Formal EU approval was still pending in the latest reports (Report).
Some clinics skip the capsule and sell NAD+ by IV drip. That route has even less human evidence behind it, as our look at NAD IV therapy found.
What We Still Don’t Know
The trials so far have been short. In the 2026 review of 15 trials, the longest lasted 24 weeks (Meta-analysis). One 24-week trial enrolled just 14 older men with diabetes. It hinted at less frailty, but the result was small enough that chance could explain it (Trial).
The outcomes that matter most are missing too. That 2026 review pooled side effects, liver tests, blood sugar and blood pressure. None of its pooled results covered disease, hospital stays or death (Meta-analysis).
The groups were narrow. Most trials enrolled healthy volunteers, and several took only men or only women. Much of the money came from industry. NMN makers funded the Indian trial and the Japanese walking, sleep and safety trials above. A Japanese company, Teijin, funded the 24-week trial (Trial).
Some results are missing. When the 2024 review’s authors searched around mid-2023, 6 finished NMN trials on ClinicalTrials.gov had posted no results (Meta-analysis).
One basic question is still open. Does more NAD+ in the blood change anything in muscle, brain or liver? The prediabetes trial shows that blood and muscle can move separately (Study).
A convincing trial would enroll several hundred people for at least a year. It would be paid for by someone with no NMN to sell. It would also measure things people feel, like strength, falls or new diabetes. The year-long trial now recruiting is a step, though it tracks age scores rather than disease (Registry).
Frequently Asked Questions
Is NMN Safe?
In short trials, it appears safe for healthy adults. A 2026 review of 10 trials and 383 people found no rise in side effects, serious side effects or liver enzymes compared with placebo (Meta-analysis). The trials lasted 24 weeks at most, so long-term safety is unknown.
How Much NMN Should I Take Daily?
No dose has clearly improved health in pooled trials, so the research cannot give you a number. Trials most often used 250 mg a day (Meta-analysis). In one trial, blood NAD+ stopped rising beyond 600 mg a day (Trial). If you want to try it, agree on a dose with a clinician.
Does NMN Reverse Aging?
There is no good evidence that it does. In the Indian trial, the NMN groups’ biological age scores held steady while the placebo group’s rose (Trial). A year-long trial that will track a combined age score, including a DNA-based clock, is still recruiting (Registry).
Is NMN the Same as NAD?
No. NMN is a raw material that your body turns into NAD+, the molecule cells use for energy and repair. Taking NMN raises NAD+ in the blood (Trial). Whether that rise reaches muscle and other tissues is less clear (Study).
Does NMN Help With Weight Loss?
The trials so far say no. In the prediabetes trial, women weighed the same after 10 weeks of NMN as before (Study). A 2026 review of 15 trials found no clear effect on body weight or BMI (Meta-analysis).
Key Takeaways
- NAD+ goes up reliably. In one 60-day trial, NMN raised blood NAD+ to three to six times its starting level, with no clear extra gain above 600 mg (Trial).
- Blood sugar: no pooled benefit. Across 8 trials and 342 adults, NMN did not improve blood sugar, insulin or cholesterol (Meta-analysis). One small trial found that muscle responded better to insulin in women with prediabetes (Trial).
- Muscle and walking: mostly no effect. Pooled trials in older adults found no gain in muscle mass, grip strength or walking speed (Meta-analysis).
- Sleep and biological age: weak evidence. Placebo groups slept better too (Trial), and the biological age result came from the placebo group aging on paper (Trial).
- Short-term safety looks fine. Pooled trials of up to 2,000 mg a day found no rise in side effects (Meta-analysis).
- The big questions are open. The trials have lasted 24 weeks at most, and none of the pooled results covered disease or death (Meta-analysis).
Should You Take NMN?
NMN does what its chemistry promises: it raises a number in your blood. When the trials are pooled, it has not made people measurably healthier. Taking it is an experiment with an unknown payoff.
If your health budget is limited, the basics have far stronger records. Regular exercise, good sleep and a decent diet have been tested for many years on outcomes that matter.
If you still want to try NMN, talk to a clinician first. That matters most if you take medicines, have diabetes, or are pregnant or breastfeeding. Stay within the doses the trials tested. And remember the sleep trial, where the dummy pill helped as much as NMN. Feeling better is not proof that it works.
Today, NMN is a reliable NAD+ booster and an unproven anti-aging supplement. The year-long trial now recruiting may start to show which way it goes.
The evidence on NMN is still coming in. Keep an eye on the trials, and trust them over the label.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a Reply